Computed tomography screening for lung cancer in the national lung screening trial a cost-effectiveness analysis

Journal of Thoracic Imaging

Volumn 30, Issue 2, 2015, Pages 79-87

  Black, William C ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

cost benefit analysis; early diagnosis; lung neoplasms mortality radiography; mass screening economics methods; quality adjusted life years; randomized controlled trials as topic; spiral computed methods; tomography

Indexed keywords

CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; RADIATION INJURY; SENSITIVITY ANALYSIS; AGED; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; FEMALE; LUNG; LUNG TUMOR; MALE; MASS SCREENING; MIDDLE AGED; RADIOGRAPHY; UNITED STATES;

AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 84924206342     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0000000000000136     Document Type: Conference Paper

References (45)

1. American Cancer Society. Cancer Facts &Figure 2014. Atlanta, GA. Available at: http://www.cancer.org/cancer/lungcancer/inDex. Accessed October 23, 2014.
2. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
3. Pinsky PF, Church TR, Izmirlian G, et al. The National Lung Screening Trial: results stratified by Demographics, smoking history, and lung cancer histology. Cancer. 2013;119: 3976-3983.
4. Gareen IF, Duan F, Greco EM, et al. Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. Cancer. 2014;120:3401-3409.
5. Pinsky PF, Gierada DS, Hocking W, et al. National lung screening trial findings by age: medicare-eligible versus unDer-65 population. Ann Intern Med. 2014;161:627-633.
6. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371:1793-1802.
7. Neumann PJ, Cohen JT, Weinstein MC. Updating costeffectiveness-The curious resilience of the 50, 000-per-QALY threshold. N Engl J Med. 2014;371:796-797.
8. Gold MR, Siegel JE, Russell LB, Weinstein MC. Costeffectiveness in Health and Medicine. Oxford: Oxford University Press; 1996.
9. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306:1865-1873.
10. Russell LB, Gold MR, Siegel JE, et al. The role of costeffectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276: 1172-1177.
11. Moyer VA. Force USPST. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330-338.
12. Arias E. United States life tables, 2009. Natl Vital Stat Rep. 2014;62:1-63.
13. Surveillance, EpiDemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER Stat Database: InciDence-SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (1973-2010 varying), April 2013. Available at: http://www.seer.cancer.gov/data/seerstat/nov2012. Accessed April 2013.
14. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271-292.
15. Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life inDexes from the National Health Measurement study. Med Care. 2007;45:1162-1170.
16. Centers for Medicare &Medicaid Services. Physician Fee Schedule Look-up tool. Available at: http://www.cms.hhs.gov/pfslookup/02-PFSsearch.asp. Accessed Mar 1, 2011.
17. Centers for Medicare &Medicaid Services. Acute Inpatient PPS. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/inDex.html. Accessed August 20, 2013.
18. Heitman SJ, Au F, Manns BJ, et al. Nonmedical costs of colorectal cancer screening using CT colonography. J Am Radiol. 2010;7:943-948.
19. Employer costs for employee compensation-December 2009, 2010. Available at: http://www.bls.gov/news.release/archives/ecec-03102010.pdf. Accessed March 1, 2011.
20. US General Services Administration. Privately owned vehicle (POV) mileage reimbursement rates. 2012. Available at: http://www.gsa.gov/portal/content/103969.
21. Priola AM, Priola SM, Giaj-Levra M, et al. Clinical implications and adDed costs of inciDental findings in an early Detection study of lung cancer by using low-dose spiral computed tomography. Clin Lung Cancer. 2013;14:139-148.
22. Kucharczyk MJ, Menezes RJ, McGregor A, et al. Assessing the impact of inciDental findings in a lung cancer screening study by using low-dose computed tomography. Can Assoc Radiol J. 2011;62:141-145.
23. De Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative moDeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:311-320.
24. Berrington De Gonzalez A, Kim KP, Berg CD. Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiationinduced cancer risk. J Med Screen. 2008;15:153-158.
25. Briggs AH, WonDerling DE, Mooney CZ. Pulling costeffectiveness analysis up by its bootstraps: a non-parametric approach to confiDence interval estimation. Health Econ. 1997;6:327-340.
26. Stinnett AA. Adjusting for bias in C/E ratio estimates. Health Econ. 1996;5:470-472.
27. Fenwick E, Marshall DA, Levy AR, et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006;6:52.
28. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368: 728-736.
29. Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2012;157: 776-784.
30. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605-613.
31. Patz EF Jr., Pinsky P, Gatsonis C, et al. Overdiagnosis in lowdose computed tomography screening for lung cancer. JAMA Int Med. 2014;174:269-274.
32. American College of Radiology. Lung Imaging Reporting and Data System (Lung-RADSs). 2014. Available at: http://www.acr.org/Quality-Safety/Resources/LungRADS. Accessed November 14, 2014.
33. MahaDevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in olDer adult smokers: a Decision and cost-effectiveness analysis. JAMA. 2003;289:313-322.
34. Manser R, Dalton A, Carter R, et al. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer. 2005;48:171-185.
35. Marshall D, Simpson KN, Earle CC, et al. Potential costeffectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer. 2001;32:227-236.
36. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6:1841-1848.
37. Pyenson BS, SanDer MS, Jiang Y, et al. An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. Health Aff. 2012;31:770-779.
38. Wisnivesky JP, Mushlin AI, Sicherman N, et al. The costeffectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest. 2003;124:614-621.
39. Van Den Bergh KA, Essink-Bot ML, Borsboom GJ, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer. 2010; 102:27-34.
40. Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of inciDent lung cancers would be covered?. J Med Screen. 2012;19:154-156.
41. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307:2418-2429.
42. McKee BJ, Regis SM, McKee AB, et al. Performance of ACR Lung-RADS in a Clinical CT Lung Screening Program. J Am Coll Radiol. 2014. DOI: http://dx.doi.org/10.1016/j.jacr.2014. 08.004.
43. Berland LL, Silverman SG, Gore RM, et al. Managing inciDental findings on abdominal CT: white paper of the ACR inciDental findings committee. J Am Coll Radiol. 2010;7: 754-773.
44. Proposed Decision memo for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). Available at: http://www.cms.gov/medicare-coverage-database/Details/nca-Details.aspx?NCAId=274&bc=AiAAAAAAAAAAAA% 3d%3d&. 2014. Accessed November 10, 2014.
45. Detterbeck FC, Unger M. Screening for lung cancer: moving into a new era Ann Intern Med. 2014;160:363-364